💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tacrolimus Anhydrous

CHEMBL269732 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
804.0 g/mol
LogP
2.7
Phase
4

A anhydrous salt form of tacrolimus with the same therapeutic properties. This medication suppresses the immune system to prevent the body from rejecting a transplanted organ such as a kidney, liver, or heart.

น้ำหนักโมเลกุล

804.0000 g/mol

LogP

2.70

TPSA

178.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

Infectious Disease Melanoma Age-Related Macular Degeneration Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Immunology Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Transplant Medicine Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Hepatitis C Cardiovascular Disease Prostate Cancer Leukemia

กลไกการออกฤทธิ์

Calcineurin inhibitor binding FKBP12; suppresses IL-2 transcription.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Calcineurin inhibitor binding FKBP12; suppresses IL-2 transcription.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC

                

                

                
                

                    
InChI

                    
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C44H69NO12

                    

                    
                    

                        
HBD / HBA

                        
3 / 12

                    

                    
                    

                        
พันธะที่หมุนได้

                        
7

                    

                    
                    
                    

                        
อะตอมหนัก

                        
57

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A anhydrous salt form of tacrolimus with the same therapeutic properties. This medication suppresses the immune system to prevent the body from rejecting a transplanted organ such as a kidney, liver, or heart.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Calcineurin inhibitor binding FKBP12; suppresses IL-2 transcription.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tacrolimus Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL269732.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 445643.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.